Indegene (INDGN) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue reached INR 6,765 million, up 11.4% year-over-year, with PAT at INR 877 million, up 28.3% year-over-year, and EBITDA margin at 19.6%.

• Achieved zero-debt status after full repayment of a $48 million loan, enhancing financial flexibility and PAT margin.

• Maintained robust client relationships, with 65 active clients and 68% of revenue from top 20 global biopharma companies.

• Board approved unaudited standalone and consolidated financial results for Q1 FY25, with auditor's limited review and unmodified opinion.

• IPO completed in May 2024, with shares listed on NSE and BSE, raising INR 7,600 million via fresh issue and INR 10,818 million via offer for sale.

Financial highlights

• Q1 FY25 revenue from operations was INR 6,765 million, up 11.4% YoY and 0.5% sequentially, with PAT at INR 877 million and EBITDA margin at 19.6%.

• PAT margin improved to 13% from 11.3% a year ago, driven by higher interest income and lower depreciation.

• Return on equity post-IPO remains healthy at 21%, and return on capital employed (net of cash) is 48%.

• Cash and cash equivalents stood at INR 13,973 million as of June 30, 2024.

• Basic EPS (consolidated) for Q1 FY25 was INR 3.79, up from INR 3.09 in Q1 FY24.

Outlook and guidance

• Management expects robust medium- to long-term growth, with a healthy pipeline and stronger H2 performance.

• Four strategic wins from mid-size pharma in Q1 are expected to drive growth in coming quarters.

• Emphasis on evaluating performance annually or over three-year periods due to industry dynamics.

• No explicit forward-looking guidance provided, but recent IPO and acquisitions indicate growth focus.